Clinical Trial Update: Safety Study of Combination Therapy With Intramuscular Avonex and Oral Cellcept in Patients With Multiple Sclerosis [Phase 2, Phase 3]

View source ↗

Summary

A completed Phase 2/3 safety trial evaluating the combination of Avonex (interferon beta-1a) and CellCept (mycophenolate mofetil) in patients with multiple scle…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Multiple Sclerosis

Drugs mentioned

• Avonex (Interferon beta-1a)
• CELLCEPT (mycophenolate mofetil hydrochloride)

Snippet

Sponsor: University of Texas Southwestern Medical Center | Conditions: Multiple Sclerosis | Phase 2, Phase 3 | Status: COMPLETED